Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (PHAT) is a clinical-stage biopharmaceutical company advancing innovative treatments through its FDA-approved therapy vonoprazan. This page aggregates all essential updates related to PHAT's progress in gastrointestinal medicine, providing investors and medical professionals with a centralized news source.
Discover official announcements covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated selection emphasizes transparency, offering neutral reporting on financial results, research breakthroughs, and market expansion efforts without investment bias.
Key focus areas include vonoprazan's commercialization progress, new therapeutic applications under investigation, and analyses of PHAT's role in evolving acid suppression therapies. Content is maintained to reflect the company's position at the forefront of GI treatment innovation.
Bookmark this page for streamlined access to Phathom's verified announcements. Regular updates ensure stakeholders stay informed about developments shaping the company's trajectory in biopharmaceutical markets.
Phathom Pharmaceuticals reported net revenues of $1.9 million for the first full quarter of launch, with over 17,500 prescriptions dispensed, representing a 361% increase. Cigna Healthcare added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of all U.S. commercial lives. The company is hosting a conference call to discuss the positive progress of VOQUEZNA in treating Erosive GERD. A direct-to-consumer campaign is actively increasing brand awareness, with future clinical trials and expanded indications on the horizon.
Phathom Pharmaceuticals, Inc. will report its first quarter 2024 financial results and provide a business update on Thursday, May 9, 2024. The company, listed on Nasdaq as PHAT, focuses on developing and commercializing novel treatments for gastrointestinal diseases. A live webcast will be hosted at 8:30 am ET on the mentioned date, with access to the presentation available on the company's website.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
